GluGene Therapeutics Secures Initial Financial Investor Participation in Series A Financing Round

GluGene Therapeutics, a biotechnology company developing advanced adeno-associated virus (AAV) platform technologies for next-generation gene therapies, announced that participation by its first financial investor (FI) is progressing successfully as part of the company’s ongoing Series A financing round.
According to industry sources, GluGene Therapeutics is currently raising capital through its Series A round to accelerate the development and commercialization of its proprietary AAV engineering platforms, including the library-based ATLAS platform, the AI-driven AIMING platform, and the manufacturing-focused GRADE platform. Together, these technologies address key biological and translational challenges associated with in vivo gene therapy, positioning the company as a platform provider capable of supporting a broad range of therapeutic indications.
Dr. Moon Sue Lee, Chief Executive Officer of GluGene Therapeutics, stated that the company is currently conducting non-human primate validation studies for its pulmonary arterial hypertension gene therapy pipeline and is targeting licensing agreements with domestic and global pharmaceutical partners beginning in 2026. In parallel, multiple proprietary AAV vectors undergoing primate-level validation for commercial applications are expected to enter active business development and strategic partnering discussions starting in 2026.
Through its data-driven AAV capsid engineering platforms and an expanding preclinical validation portfolio, GluGene Therapeutics aims to establish itself as a leading global partner in engineered AAV vectors, supporting both internal pipeline advancement and external licensing opportunities across diverse gene therapy indications.